NEW YORK (GenomeWeb News) – Memorial Sloan-Kettering Cancer Center has received what it believes is the first approval from the New York State Department of Health to use Sequenom's MassArray Compact 384 system for diagnosing gene mutations in patients.
The hospital will use the instrument to look for mutations in EGFR, KRAS, and BRAF in biopsy samples in patients with lung, colorectal, and thyroid cancers, as well as melanoma. The platform will also allow researchers at MSKCC to investigate mutations in lesser known genes and enroll patients in clinical trials for new, experimental targeted drugs.
Marc Ladanyi, chief of the Molecular Diagnostics Service and director of the Diagnostic Molecular Pathology Laboratory at MSKCC, led the team that developed the protocols and validated the Sequenom platform for clinical applications.
Ladanyi could not be reached for comment, but in MSKCC's newsletter, he said, "To our knowledge, we are the only hospital to have New York State approval to use the technology for this purpose."
At publication time, the NYS Department of Health had not confirmed that statement for GenomeWeb Daily News.
Last month, Sequenom launched the next iteration of the MassArray platform, called MassArray Analyzer 4.